Interpreted Prediction
Predicted One Source's performance will be lumpy in FY26.
AI Evaluation Notes
OneSource Specialty Pharma's FY26 has shown a 'lumpy' performance thus far. The company reported a consolidated net loss in Q1 FY26, followed by robust financial results with a 12% year-over-year revenue growth in Q2 FY26.